Business Wire

Venture Global Announces Commencement of Commercial Operations at Calcasieu Pass

Share

Today, Venture Global announced that it has notified its long-term customers that its Calcasieu Pass facility will commence commercial operations on April 15, 2025. The facility will achieve its commercial operation date, or COD, in under 68 months from its August 2019 final investment decision, despite substantial impacts including two hurricanes, the COVID-19 pandemic, and major unforeseen manufacturing issues, such as with the Heat Recovery Steam Generators (HRSGs) forming part of the facility’s power island.

Venture Global wishes to express its gratitude to its construction and completion teams who tirelessly worked to safely complete our facilities, to our vendor teams who provided invaluable support for the necessary repairs, and to our government regulators, including the Federal Energy Regulatory Commission, for their oversight and cooperation. These efforts now allow us to supply our long-term customers with the full 20-year contract term of the lowest-cost, clean LNG as promised under our contracts, and, with our COD, makes Calcasieu Pass among the fastest greenfield LNG projects completed.

About Venture Global

Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capacity to provide clean, affordable energy to the world. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

Forward-looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this press release are forward-looking statements. Forward-looking statements include statements concerning the offering, Venture Global’s plans, objectives, goals, strategies, future events or performance, capital expenditures, financing needs, ability to fund operations, timelines for development and construction of its projects and commencement of operation at its projects, intentions relating to acquisitions, competitive strengths and weaknesses, and business strategy; and other information that is not historical information. Words such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “forecast”, “project”, “target”, “plan” or “aim” or terms of similar meaning are also generally intended to identify forward-looking statements. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Venture Global undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217187997/en/

Contacts

Investor Contact
Michael Pasquarello
IR@ventureglobalLNG.com

Media Contact
Shaylyn Hynes
press@ventureglobalLNG.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release

Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu

SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release

SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer

SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc

SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 12:00:00 EET | Press release

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye